key: cord-0287612-kk2z15x4
authors: Li, Jian; Lin, Cheng; Zhou, Xuelan; Zhong, Fanglin; Zeng, Pei; Yang, Yang; Zhang, Yuting; Yu, Bo; Fan, Xiaona; McCormick, Peter J.; Fu, Rui; Fu, Yang; Jiang, Haihai; Zhang, Jin
title: Structural basis of main proteases of coronavirus bound to drug candidate PF-07321332
date: 2021-11-08
journal: bioRxiv
DOI: 10.1101/2021.11.05.467529
sha: 1f4d70e23f41510abe9ed9ddd9220ebbecdb2d1c
doc_id: 287612
cord_uid: kk2z15x4

The high mutation rate of COVID-19 and the prevalence of multiple variants strongly support the need for pharmacological options to complement vaccine strategies. One region that appears highly conserved among different genus of coronaviruses is the substrate binding site of the main protease (Mpro or 3CLpro), making it an attractive target for the development of broad-spectrum drugs for multiple coronaviruses. PF-07321332 developed by Pfizer is the first orally administered inhibitor targeting the main protease of SARS-CoV-2, which also has shown potency against other coronaviruses. Here we report three crystal structures of main protease of SARS-CoV-2, SARS-CoV and MERS-CoV bound to the inhibitor PF-07321332. The structures reveal a ligand-binding site that is conserved among SARS-CoV-2, SARS-CoV and MERS-CoV, providing insights into the mechanism of inhibition of viral replication. The long and narrow cavity in the cleft between domains I and II of main protease harbors multiple inhibitor binding sites, where PF-07321332 occupies subsites S1, S2 and S4 and appears more restricted compared with other inhibitors. A detailed analysis of these structures illuminated key structural determinants essential for inhibition and elucidated the binding mode of action of main proteases from different coronaviruses. Given the importance of main protease for the treatment of SARS-CoV-2 infection, insights derived from this study should accelerate the design of safer and more effective antivirals.

Since its discovery in Dec 2019, cases of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pneumonia have rapidly continued to emerge, with the current case count close to 250 million and a case mortality rate ~3.4%, causing huge economic and social loss to the world. [1, 2] There have been several coronaviruses in human history that are pathogenic to humans, among which two were associated with severe respiratory disease outbreaks: SARS-CoV (severe acute respiratory syndrome coronavirus first emerged in Guangdong China in 2002) and MERS-CoV (Middle East respiratory syndrome coronavirus first detected in Saudi Arabia in 2012). [3] [4] [5] Genomic sequencing data showed that SARS-CoV-2 shares 79.6% sequence identity with SARS-CoV. [1, [6] [7] [8] As SARS-CoV and SARS-CoV-2 successively emerged and COVID-19 continues spreading throughout the globe, developing broad spectrum drugs remains an urgent and unmet clinical need in the treatment and prevention of COVID-19 infections.

Viral enzymes and proteins of CoVs that are involved in coronavirus replication are potential drug targets for COVID- 19 . In particular, the main protease (M pro or 3CL pro ), which cleaves the replicase polyproteins at 11 sites, is one of the most attractive targets for numerous classes of small molecule inhibitors for the development of drugs against coronavirus infections. [9, 10] M pro is highly conserved among coronaviruses, and the substrate-binding site in M pro also share several common features. [6] Because M pro has no human homolog, M pro inhibitors should be highly specific to SARS-CoV-2 and have minimal side effects. [11] Unfortunately, although several peptidomimetic covalent inhibitors of M pro have been reported, few candidates has progressed into clinical trials. [6, [12] [13] [14] We previously screened an in-house small molecule library and identified shikonin as a noncovalent inhibitor for SARS-CoV-2 and SARS-CoV M pro in vitro, with a half-maximum inhibitory concentration (IC50) of 1.57 μ M and 7.89 μ M, respectively. [15, 16] Besides, crystal structures of SARS-CoV-2 M pro with antineoplastic drug carmofur and natural products baicailin and baicalein have also been solved recently [17, 18] . Despite the progress made in understanding the origin of human coronaviruses as well as the prediction and prevention of the emerging pandemics, we still lack effective and safe drugs and therapies to combat the global pandemic caused by coronavirus. [5, 19, 20] In March 2021, Pfizer has initiated a Phase 1 clinical trial of a novel antiviral therapeutic agent against SARS-CoV-2. The clinical candidate, PF-07321332, is the first orally administered coronavirus-specific protease inhibitor, which has shown potency in vitro anti-viral activity against SARS-CoV-2, as well as activity against other coronaviruses. [21] As a protease inhibitor, PF-07321332 binds to the viral enzyme and can block the activity of the protease that the coronavirus needs to reproduce itself. This kind of inhibitors have effectively treated other viral pathogens, such as HIV and hepatitis C virus. As there is currently no orally administered therapy approved for the post-exposure or pre-emptive treatment of COVID-19, PF-07321332 could be an encouraging therapeutic with potential for use in the treatment of COVID-19, as well as potential use to address future coronavirus threats.

In this study, we aim to explore the molecular basis for the small molecule inhibitor PF-07321332 targeting M pro of coronaviruses. We found that PF-07321332 potently inhibits the enzymatic activity of SARS-CoV-2 M pro . We then determined the crystal structures of complexes of main protease of SARS-CoV-2, SARS-CoV and MERS-CoV bound to the inhibitor PF-07321332, revealing a novel binding mode of M pro . Structural comparison with reported M pro -inhibitor complex structures provides an insight into the mechanism of M pro inhibition by a small molecule inhibitor and a framework for small molecule drug discovery.

We purified the M pro of SARS-CoV-2 as previously reported [15] . A Fluorescence Resonance Energy Transfer (FRET) assay was employed to determine the inhibitory activity of PF-07321332 against SARS-CoV-2 M pro . Ebselen was used as a control with an IC50 value of 0.365 μ M, which is similar to previous studies [22] [23] . The results showed that PF-07321332 has a potent inhibition with the IC 50 value against the M pro of SARS-CoV-2 being 0.023 μ M (Fig. 1) , which is much lower that recently reported covalent inhibitors such as boceprevir, leupeptin, and carmofur [24] [25] [26] .

In order to figure out the inhibitory mechanisms of PF-07321332, we determined the crystal structure of SARS-CoV-2 M pro in complex with PF-07321332 (PFM pro -Co) at 1.5 Å resolution by co-crystallization method (Table 1) . By comparison with the apo structure of SARS-CoV-2 M pro at pH 7.5, the root mean square deviation (RMSD) of equivalent C positions between apo Mpro and PFM pro -Co is ~ 0.985 Å (Fig. S1 ). As shown in Fig. 2 , the M pro molecule in the complex structure forms a homodimer and contains three domains, namely domain I (residues 10-99), domain II (residues 100-184), and domain III (residues 201-303). PF-07321332 can be found in both protomer A and protomer B (Fig. 2a) . Specifically, PF-07321332 binds to the active site situated in the cleft between domains I and II of M pro in an extended conformation and occupies subsites S1, S2 and S4 of SARS-CoV-2 M pro (Fig. 2b) . The electron density map unambiguously shows that nitrile carbon of PF-07321332 forms a C-S covalent bond with the sulfur atom of catalytic residue C145 (Fig. 2c) . The imine nitrogen of the thioimidate moiety occupies the oxyanion hole and forms hydrogen bonds with the backbone NH of C145 and the oxygen from a water molecule for stabilization. Besides the typical covalent interaction, PF-07321332 forms multiple non-covalent interactions with the active site. According to the Berger and Schechter nomenclature, PF-07321332 consists of five moieties, namely P1-P4 and P1'. As shown in Fig. 2d and 2e, PF-07321332 contains a γ -lactam ring at P1 position just before the warhead nitrile group. The lactam ring inserts into the S1 subsite with the oxygen and nitrogen atoms of the lactam ring forming hydrogen bonds with the Nε2 of H163 and carboxy group of E166, respectively. Further, a hydrogen bond is also found between the amide nitrogen at the P1 moiety and the main-chain carbonyl oxygen of H164. The P2 position contains a dimethylcyclopropylproline (DMCP) moiety which inserts into the S2 subsite and mainly forms hydrophobic interactions, similar with the previously reported compound boceprevir [25] . PF-07321332 presents a tert-leucine residue at P3 position. However, limited interactions are observed between P3 moiety of PF-07321332 and S3 subsite of M pro . PF-07321332 displays a trifluoromethyl group at P4 position. The amide nitrogen at P4 position forms a hydrogen bond with the main chain carbonyl oxygen of E166, while the trifluoromethyl group forms additional hydrogen bonds by interacting with the nitrogen atom of Q192 and a water molecule. Thus, PF-07321332 occupies the active site of SARS-CoV M pro by covalently binding to C145 and noncovalently interacting with conserved residues including Cy145, H163, H164, E166 and Q192.

The crystal structure of M pro -PF-07321332 complex (PFM pro -So) has also been solved at 1.9 Å resolution by soaking (Table 1) . By superimposition of PFM pro -Co and PFM pro -So, we found that the binding mode of PF-07321332 with SARS-CoV-2 Mpro was highly similar with the RMSD being 0.781 Å over the 523 best-aligned Cα atoms (Fig. S2 ).

We also determined the crystal structure of PF-07321332 in complex with SARS-CoV and MERS-CoV M pro at 2.0 Å and 2.5 Å resolution (Table 1) , respectively. PF-07321332 displays a highly similar conformation in the substrate-binding site of SARS-CoV, MERS-CoV, and SARS-CoV-2 M pro even though the orientation of each moiety of PF-07321332 has slight differences ( Fig. 3a and 3b ). Like the case with SARS-CoV-2 M pro , PF-07321332 fits into the S1, S2 and S4 subsites, and forms a covalent bond with the catalytic residue cysteine as expected ( Fig. 3c and 3d ). In addition, several amino acid residues, including F140, C145, H163, H164, E166 and Q192, in the protease form hydrogen bond interactions with the inhibitor in the SARS-

The key residues of MERS-CoV M pro interacting with PF-07321332 is highly conserved (Fig. 3e-3h ). These observations are consistent with the fact that the structure of M pro in the coronaviruses is highly conserved and that PF-07321332 may be a potent inhibitor with broad-spectrum potential to defeat diseases caused by various coronaviruses.

We also compared the structures of the recently identified covalent inhibitors complexed with SARS-CoV-2 M pro . All these small molecules form a C-S covalent bond with the catalytic residue cysteine (Fig. 4) and display a lactam ring at P1 position which fits well with the S1 

There is an urgent need to develop effective drugs as the novel coronavirus pandemic continues to wreak havoc on human society. M pro is a promising drug target for its vital role in viral replication, high conservation among all coronavirus, and has no homolog in humans. Although a great number of inhibitors have been found to show inhibitory activity at M pro , most of these are not potent enough and not highly bioavailable following oral administration, which functionally limits its clinical application to hospitalized patients with relatively advanced disease. Thus, potent orally bioavailable antiviral drugs for treatment of SARS-CoV-2 infection are urgently needed. PF-07321332 is a SARS-CoV-2 M pro inhibitor developed by Pfizer in clinical trial [27] . In this study, we found PF-07321332 is a potent inhibitor with a IC 50 being 0.023 μ M. Though this value is a little higher than MPI3, the most potent inhibitor of SARS-CoV-2 M pro so far [28] , but lower than most reported inhibitors including 11a (IC 50 =0.053 μ M) [29] , 13b (IC 50 =0.67 μ M) [30] , boceprevir (IC 50 =8.0 μ M) [24] and GC376 (IC 50 =0.15 μ M) [24] , which implicates its huge potential to treat COVID-19 clinically. In addition, the main advantage of PF-07321332 with respect to other inhibitors of SARS-CoV-2 M pro is the possibility of oral administration, a feature that could dramatically facilitate the treatment of COVID-19.

We also solved the crystal structure of PF-07321332 in complex with M pro of three deadly coronoviruses (SARS-CoV-2, SARS-CoV and MERS), which is of great importance for structure-based drug development. The complex structures indicate that PF-07321332 covalently bound to the catalytic cysteine of M pro , and formed multiple hydrogen bonds with conserved residues within the active site. By comparing with other covalent inhibitors, PF-07321332 employs a unique binding pattern to SARS-CoV-2 M pro . Further structure-based optimization of such covalent inhibitors will help generate drugs against current COVID-19 pandemic with high efficiency and broad-spectrum.

Besides PF-07321332, another orally bioavailable drug candidate, masitinib, has been demonstrated to show inhibitory effect against SAR-CoV-2 M pro . Up to now, masitinib has been approved for treatment of mast cell tumors in dogs and evaluated in phase 2 and 3 clinical trials in humans for the treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis [31] . However, unlike PF-07321332 as a covalent inhibitor, masitinib is a non-covalent inhibitor, which could complement the design of covalent inhibitors against SARS-CoV-2 main protease. Both covalent and non-covalent M pro inhibitor will contribute to increase public health preparedness for potential future pandemic.

The codon-optimized cDNAs for M pro of SARS-CoV-2, SARS and MERS were synthesized fused with 6 His at the N terminus. Synthesized genes were subcloned into the pET-28a vector.

The expression and purification of each main protease performed by a standard method described previously by our lab. [15] Enzymatic Assays. Fluorogenic substrates as a donor and quencher pair were synthesized. The 

The crystals were tailored with cryo-loop and then flash-frozen in liquid nitrogen to collect better X-ray data. All data sets were collected at 100 K on macromolecular crystallography beamline17U1 (BL17U1) at Shanghai Synchrotron Radiation Facility (SSRF, Shanghai, China).

All collected data were handled by the HKL 2000 software package. The structures were determined by molecular replacement with PHENIX software. The program Coot was used to rebuild the initial model. The complete wanted data collection and statistics of refinement are shown in Table 1 

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster

Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia

A novel coronavirus from patients with pneumonia in china

Evidence supporting a zoonotic origin of human coronavirus strain nl63

Structure-based design of antiviral drug candidates targeting the sars-cov-2 main protease

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in china

Coronaviruses -drug discovery and therapeutic options

Coronavirus main proteinase (3cl pro ) structure: Basis for design of anti-sars drugs

The newly emerged sars-like coronavirus hcov-emc also has an "achilles' heel": Current effective inhibitor targeting a 3c-like protease

Structure of mpro from sars-cov-2 and discovery of its inhibitors

Α -ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment

Crystal structure of sars-cov-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Crystal structure of sars-cov-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode

Structure-based discovery and structural basis of a novel broad-spectrum natural product against main protease of coronavirus

Structural basis for the inhibition of sars-cov-2 main protease by antineoplastic drug carmofur

Discovery of baicalin and baicalein as novel, natural product inhibitors of sars-cov-2 3cl protease <em>in vitro</em>. bioRxiv

Bat origin of human coronaviruses

Further evidence for bats as the evolutionary source of middle east respiratory syndrome coronavirus

Pfizer initiates phase 1 study of novel oral antiviral therapeutic agent against sars-cov-2

Inhibition mechanism of sars-cov-2 main protease by ebselen and its derivatives

Structure of m(pro) from sars-cov-2 and discovery of its inhibitors

Mechanism of microbial metabolite leupeptin in the treatment of covid-19 by traditional chinese medicine herbs

Both boceprevir and gc376 efficaciously inhibit sars-cov-2 by targeting its main protease

Structural basis for the inhibition of sars-cov-2 main protease by antineoplastic drug carmofur

Computational simulations on the binding and reactivity of a nitrile inhibitor of the sars-cov-2 main protease

A quick route to multiple highly potent sars-cov-2 main protease inhibitors*

Structure-based design of antiviral drug candidates targeting the sars-cov-2 main protease

Crystal structure of sars-cov-2 main protease provides a basis for design of improved α -ketoamide inhibitors

Masitinib is a broad coronavirus 3cl inhibitor that blocks replication of sars-cov-2

We would like to thank the Cryo-EM center of Southern University of Science and Technology